Viva Vision Biotech, Strategic cooperation with Viva, will work together to overcome the problem of dry eye disease treatment
Viva Vision Biotech (Viva Vision), founded by Dr. Shen who serves as CEO. Viva Vision is a new drug research and development biotechnology company, incubating in Viva International Incubator, and funded by Hangzhou Qiandai and Beijing Daoyuan investment. Viva Vision's drug discovery emphases on the treatment of dry eye disease which is closely related with the society and our people.
Chinese ophthalmic drugs, especially the new drugs which have obvious curative effect are still lacking and cannot meet the needs of Chinese patients. For instance, since the tendency of aging population and environmental factor, Chinese dry eye disease patients increase year by year, expecting up to 50 million people suffering form moderate to severe dry eye disease.
Viva Vision will initiate the preclinical, toxicological standardization evaluation tests of new drugs
Viva Vision's first new drug will apply to treating dry eye disease. After more than one year's effort, Viva Vision has completed the drug screening. Two compound patent has been submitted, and three patents are under writing. Our preclinical candidate drugs have reached the ideal level of cell activity in vitro target. In rabbit PK experiments, the concentration of compounds in target tissues was also at the preset level. Compounds are being amplified and it is expected that the preclinical, pharmacological and toxicological tests will be initiated in October. If nothing else, we will declare clinical approval next year and officially enter the clinical trial phase.
About Dr. Shen
Dr.Shen is the Founder and Chief Executive Officer of Viva Vision Biotech. He has more than 20 years of drug discovery and project management experiences in large pharmaceutical companies such as Abbott, Amgen, Sunesis and KanionUSA. He is the principle inventor of Lifitegrast (SAR1118), a potent LFA-1 inhibitor, approved by FDA to treat dry eye disease. Also he made an importantly contribution to Venetoclax (ABT-199/GDC-0199), a selective BCL-2 inhibitor, approved by FDA in 2016 to treat certain types of leukemia. He is the co-author of over 40 peer-reviewed publications and co-inventor of over 40 patents.
Dr. Shen received his B.S. in chemistry from Fudan University and Ph.D. in Organic Chemistry from Pittsburgh University with Professor Dennis P. Curran.He did Postdoctoral training in Memorial Sloan-Kettering Cancer Center with Prof. Samuel J. Danishefsky.